ATLANTA, GA – – (Businesswire – August 21, 2019) – – Holzer & Holzer, LLC is investigating whether certain statements made by Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) complied with federal securities laws. On August 13, 2019, the Company reported lower earnings than expected and revealed that it has been in ongoing discussions with the FDA regarding the test offering of one of its products. The price of Myriad Genetics stock fell following the announcement. If you purchased shares of Myriad Genetics and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Luke R. Kennedy at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.